Johnson & Johnson, the world's largest health-products company, will eliminate about 4 percent of its workforce to save as much as US$1.6 billion next year.
The New Jersey-based company expects the job reductions to result in charges of as much as US$750 million in the second half of this year, it said in a statement yesterday.
The cuts amount to as many as 4,820 workers worldwide.
Lost revenue
Johnson & Johnson chief executive officer William Weldon's cost savings announced yesterday will help the company weather lost revenue when two best-selling drugs, the migraine pill Topamax, with US$2 billion in sales last year, and the schizophrenia treatment Risperdal, with US$4.2 billion in revenue last year, face stiff competition next year because of cheaper generic copies.
Most of the savings will occur in the pharmaceuticals division, "which faces significant patent expirations over the next few years" and in the Cordis division, which makes drug-coated stents, the company said.
Cutting costs
Many drug makers are cutting costs as the result of generic competition to older medicines that are losing patent protection. Last year Merck & Co began eliminating 7,000 jobs and closing plants. In January, Pfizer Inc, the world's largest drug maker, said it would eliminate 10,000 jobs.
On Thursday, London-based AstraZeneca Plc said it would decrease its workforce by 11 percent and Bristol-Myers Squibb Co said it would announce job cuts by the end of the year.
Earnings forecast
Johnson & Johnson reaffirmed its earnings forecast of US$4.02 to US$4.07 a year excluding some items, and said that it will maintain its investments in research and development.
Johnson & Johnson also said it may introduce as many as 10 new medicines by 2011.
On July 17, it lowered its revenue growth forecast for this year, citing reduced prospects for US sales of Cypher stents and the anemia drug Procrit, both linked to heart attacks in studies. The company projected revenue growth this year of 11.5 to 12 percent, down from 11.5 to 12.5 percent.
Sales of the Cypher stent, a tiny mesh tube used to prop open arteries after surgery, fell 41 percent to US$210 million in the US in the second quarter, the company said on July 17.
Sales outside the US fell 30 percent to US$240 million, it said.
Procrit revenue fell 6 percent to US$758 million, spurred by a 15 percent drop in US sales, the company said.
Outside the US, revenue for the drug grew 9 percent to US$309 million. Procrit use slowed after studies showed it may raise the risk of heart attacks, strokes and deaths at high doses.
Nvidia Corp yesterday unveiled its new high-speed interconnect technology, NVLink Fusion, with Taiwanese application-specific IC (ASIC) designers Alchip Technologies Ltd (世芯) and MediaTek Inc (聯發科) among the first to adopt the technology to help build semi-custom artificial intelligence (AI) infrastructure for hyperscalers. Nvidia has opened its technology to outside users, as hyperscalers and cloud service providers are building their own cost-effective AI chips, or accelerators, used in AI servers by leveraging ASIC firms’ designing capabilities to reduce their dependence on Nvidia. Previously, NVLink technology was only available for Nvidia’s own AI platform. “NVLink Fusion opens Nvidia’s AI platform and rich ecosystem for
WARNING: From Jan. 1 last year to the end of last month, 89 Taiwanese have gone missing or been detained in China, the MAC said, urging people to carefully consider travel to China Lax enforcement had made virtually moot regulations banning civil servants from making unauthorized visits to China, the Control Yuan said yesterday. Several agencies allowed personnel to travel to China after they submitted explanations for the trip written using artificial intelligence or provided no reason at all, the Control Yuan said in a statement, following an investigation headed by Control Yuan member Lin Wen-cheng (林文程). The probe identified 318 civil servants who traveled to China without permission in the past 10 years, but the true number could be close to 1,000, the Control Yuan said. The public employees investigated were not engaged in national
ALL TOGETHER: Only by including Taiwan can the WHA fully exemplify its commitment to ‘One World for Health,’ the representative offices of eight nations in Taiwan said The representative offices in Taiwan of eight nations yesterday issued a joint statement reiterating their support for Taiwan’s meaningful engagement with the WHO and for Taipei’s participation as an observer at the World Health Assembly (WHA). The joint statement came as Taiwan has not received an invitation to this year’s WHA, which started yesterday and runs until Tuesday next week. This year’s meeting of the decisionmaking body of the WHO in Geneva, Switzerland, would be the ninth consecutive year Taiwan has been excluded. The eight offices, which reaffirmed their support for Taiwan, are the British Office Taipei, the Australian Office Taipei, the
CAUSE AND EFFECT: China’s policies prompted the US to increase its presence in the Indo-Pacific, and Beijing should consider if this outcome is in its best interests, Lai said China has been escalating its military and political pressure on Taiwan for many years, but should reflect on this strategy and think about what is really in its best interest, President William Lai (賴清德) said. Lai made the remark in a YouTube interview with Mindi World News that was broadcast on Saturday, ahead of the first anniversary of his presidential inauguration tomorrow. The US has clearly stated that China is its biggest challenge and threat, with US President Donald Trump and US Secretary of Defense Pete Hegseth repeatedly saying that the US should increase its forces in the Indo-Pacific region
RSS